Wuhan Hiteck Biological Pharma Co.,Ltd (SHE:300683)

China flag China · Delayed Price · Currency is CNY
32.72
-0.49 (-1.48%)
Mar 20, 2026, 3:04 PM CST
Market Cap4.28B +41.6%
Revenue (ttm)619.88M +0.8%
Net Income-187.70M
EPS-1.45
Shares Out130.89M
PE Ration/a
Forward PEn/a
Dividend0.13 (0.39%)
Ex-Dividend Daten/a
Volume4,948,700
Average Volume7,053,400
Open37.91
Previous Close33.21
Day's Range32.70 - 37.91
52-Week Range19.00 - 61.76
Beta0.31
RSI48.73
Earnings DateApr 24, 2026

About SHE:300683

Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Epramine for injection; mouse nerve growth factor for injection; Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome; adenosine cyclophosphate for injection that is used for angina pec... [Read more]

Sector Healthcare
Founded 1992
Employees 1,309
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300683
Full Company Profile

Financial Performance

In 2024, SHE:300683's revenue was 648.97 million, an increase of 7.75% compared to the previous year's 602.28 million. Losses were -69.35 million, -42.60% less than in 2023.

Financial Statements